List of Excipients in Branded Drug DYE FREE WAL ZYR

Generic Drugs Containing DYE FREE WAL ZYR

Company	Ingredient	NDC	Excipient
Walgreen Company	cetirizine hydrochloride	0363-1974	ACETIC ACID
Walgreen Company	cetirizine hydrochloride	0363-1974	GLYCERIN
Walgreen Company	cetirizine hydrochloride	0363-1974	METHYLPARABEN

What are the Most Frequently-Used Excipients in DYE FREE WAL ZYR?

# Of NDCs	Excipient
1	ACETIC ACID
1	GLYCERIN
1	METHYLPARABEN

DYE FREE WAL ZYR Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

DYE FREE WAL ZYR is a private-label cetirizine hydrochloride allergy product positioned around the absence of artificial colorants. Its commercial value comes from low-cost OTC manufacture, broad allergy demand, and a differentiated excipient profile rather than from active-ingredient exclusivity. Cetirizine is an established antihistamine with no meaningful current patent barrier to generic or private-label competition. The strongest opportunities are in clean-label positioning, pediatric-friendly dosage forms, unit-dose packaging, e-commerce, and retailer-exclusive formulations.

What is DYE FREE WAL ZYR?

DYE FREE WAL ZYR is Walgreens’ private-label version of a cetirizine allergy medicine. The product is generally marketed as a 10 mg oral tablet containing cetirizine hydrochloride, equivalent to 10 mg of cetirizine.

The product competes with Zyrtec, store-brand cetirizine, loratadine products such as Claritin, and fexofenadine products such as Allegra. Its primary consumer claim is the absence of color additives, not a novel active ingredient or delivery system.

Exact excipients can vary by product configuration, manufacturer, and National Drug Code. The relevant regulatory record is the package label for the specific NDC. Typical cetirizine tablet formulations use standard direct-compression or wet-granulation excipients such as:

• Microcrystalline cellulose
• Lactose or another diluent
• Croscarmellose sodium or a comparable disintegrant
• Povidone or another binder
• Colloidal silicon dioxide
• Magnesium stearate
• Film-coating polymers
• Titanium dioxide or other opacifying agents in some formulations

A product described as dye-free may still contain other color-related materials, including titanium dioxide, depending on its coating and labeling. "Dye-free" does not necessarily mean "colorant-free," "artificial-ingredient-free," or "hypoallergenic."

What excipient strategy protects the commercial position of DYE FREE WAL ZYR?

The excipient strategy is primarily a consumer-positioning and manufacturing strategy. It is unlikely to create meaningful patent exclusivity by itself.

Dye-free positioning

Removing FD&C or D&C color additives can appeal to consumers who avoid artificial dyes, parents purchasing pediatric medicines, and customers with perceived sensitivity to colorants. The claim is simple to communicate and can differentiate a private-label product from visually colored tablets.

The commercial tradeoff is that colorants can improve product identification, coating uniformity, and brand recognition. A dye-free formulation must preserve tablet appearance, stability, swallowability, and packaging differentiation without relying on colored coatings.

Tablet manufacturability

Cetirizine tablets are typically designed for high-volume, low-cost production. Excipient selection must support:

• Uniform distribution of the low-dose active ingredient
• Consistent tablet weight and hardness
• Rapid disintegration
• Low friability during bottling and shipping
• Stable dissolution over shelf life
• Efficient high-speed compression
• Acceptable powder flow and low segregation risk

Microcrystalline cellulose and a superdisintegrant can support direct compression. Magnesium stearate controls tooling friction but can slow dissolution if overused or overmixed. Colloidal silicon dioxide improves flow but must be optimized to avoid changes in blend density and content uniformity.

Lactose and allergen perception

Lactose is common in oral solid dosage forms, but some consumers seek lactose-free products. A lactose-free cetirizine tablet could create a second clean-label position, particularly for private-label retailers and online channels.

The commercial benefit depends on whether the target population values lactose avoidance enough to support a price premium. A lactose-free formula can also reduce concerns among consumers who confuse lactose intolerance with milk-protein allergy, although lactose-free does not automatically mean milk-protein-free.

Film coating and swallowability

A thin, clear or lightly opaque film coat can improve swallowability and reduce dust without introducing a dye. Coating must not materially delay dissolution or create a new labeling issue.

For an adult 10 mg tablet, coating optimization is more likely to provide incremental commercial value than a novel excipient. For pediatric products, taste masking and mouthfeel are more important. Cetirizine has a recognizable bitter taste, creating an opportunity for coated mini-tablets, orally disintegrating tablets, chewables, and flavored liquids.

What FDA regulatory pathway applies to DYE FREE WAL ZYR?

Cetirizine is an established OTC antihistamine active ingredient. FDA’s OTC monograph framework for antihistamine products provides the central regulatory pathway for compliant cetirizine products, subject to applicable monograph conditions, labeling, dosage, warnings, and manufacturing requirements.[1]

The product’s regulatory status depends on its specific labeling and marketing authorization. A private-label product may be marketed under an OTC monograph framework, an approved application, or another legally applicable pathway. The product label and NDC record determine the most reliable product-specific status.

FDA requirements affecting excipients

Excipients must be suitable for the dosage form and supported by accepted regulatory use. For a conventional tablet, the manufacturer typically evaluates:

• Inactive Ingredient Database precedent
• Compendial quality standards
• Residual solvents and elemental impurities
• Microbial quality
• Stability and compatibility
• Dissolution impact
• Allergen and dietary-source labeling
• Color additive compliance
• Manufacturing-process validation

A new excipient or an unusually high level of an established excipient can increase regulatory review and development risk. The lowest-risk strategy is usually a conventional excipient system with extensive oral-tablet precedent.

What patents protect DYE FREE WAL ZYR?

No publicly evident patent estate appears to protect the core commercial product concept of dye-free cetirizine tablets. The active ingredient, cetirizine, is generic and widely available. The dye-free positioning is generally a formulation choice and marketing claim, not a standalone patent right.

Potential IP categories include:

IP category	Likely relevance to DYE FREE WAL ZYR
Cetirizine composition patents	Expired or commercially exhausted for the basic active ingredient
Tablet formulation patents	Possible only if a specific composition, release profile, or manufacturing process is claimed
Dye-free formulation patents	Possible in narrow cases, but difficult to enforce against conventional tablets
Taste-masking patents	Relevant to chewable, liquid, or orally disintegrating formats
Packaging patents	Possible for unit-dose, child-resistant, or dispensing systems
Trademarks	More important than patents for "Wal-Zyr" and retailer branding
Trade dress	Potentially relevant to packaging appearance and shelf presentation

The principal competitive barriers are supply reliability, retailer procurement, quality performance, packaging compliance, cost, and shelf access.

When does cetirizine lose exclusivity?

Cetirizine lost practical market exclusivity years ago. The original branded product, Zyrtec, was developed by McNeil Consumer Healthcare, a Johnson & Johnson company, and later became widely available as an OTC generic.

The relevant commercial timeline is:

Milestone	Approximate timing	Commercial effect
Cetirizine developed and introduced as prescription therapy	1990s	Initial branded market
U.S. patent and prescription exclusivity period	Largely expired before OTC generic expansion	Entry opportunity for generic manufacturers
FDA approval of OTC switch for Zyrtec	2007	Expanded consumer access and retail demand
Broad generic and private-label availability	2007 onward	Price competition and retailer substitution
Current market	2020s	Mature OTC category with limited active-ingredient barriers

FDA’s 2007 approval allowed cetirizine to move from prescription to nonprescription use in the United States.[2] The OTC switch materially expanded the addressable market but also accelerated store-brand competition.

What is the Orange Book status of DYE FREE WAL ZYR?

DYE FREE WAL ZYR is not best analyzed as an Orange Book-protected branded product. The Orange Book is principally relevant to approved prescription and certain other FDA-approved drug applications, including listed patents and generic-equivalence determinations.[3]

For a conventional OTC monograph product:

• Orange Book patent listings may not provide the primary exclusivity analysis.
• Paragraph IV litigation is generally not the central market-entry mechanism.
• The key legal questions are monograph compliance, labeling, manufacturing quality, trademark rights, and supply contracts.
• A private-label product may have no product-specific patent listing comparable to an innovative prescription drug.

A competitor developing a conventional dye-free cetirizine tablet would normally face little active-ingredient patent risk. A company using a novel delivery system could face formulation, process, or device patents owned by another manufacturer.

Are there Paragraph IV challenges involving DYE FREE WAL ZYR?

No Paragraph IV challenge is central to the conventional DYE FREE WAL ZYR commercial model. Paragraph IV certifications apply to ANDA applicants challenging listed patents for reference products. They are not normally the relevant mechanism for a straightforward OTC monograph cetirizine product.

Paragraph IV risk could become relevant if a company develops a product relying on an approved reference drug application and the reference product has listed patents covering a novel dosage form, delivery technology, or method of use. That scenario differs from ordinary dye-free cetirizine tablets.

What formulation patents could affect future cetirizine products?

The strongest formulation IP opportunities are outside the basic dye-free tablet. They include:

Orally disintegrating tablets

An orally disintegrating cetirizine tablet could target patients who have difficulty swallowing conventional tablets. Patentable elements may include:

• Porous tablet structure
• Specific superdisintegrant combinations
• Taste-masking coatings
• Rapid disintegration time
• Low-moisture manufacturing
• Packaging that protects against humidity

Chewable tablets

Chewable products can compete for pediatric and convenience-oriented demand. The principal formulation challenges are bitterness, grittiness, tablet fracture, and flavor stability. Taste-masking systems and flavor combinations may create narrow formulation claims.

Oral liquids

Liquid cetirizine products require control of:

• Solubility
• Preservative efficacy
• pH
• Flavor stability
• Sedimentation or crystallization
• Dose-measuring accuracy

A preservative-free or low-sugar liquid could support differentiated positioning, although it would carry higher microbiological and packaging risk than a tablet.

Combination products

Cetirizine combined with pseudoephedrine or another decongestant can create additional commercial value, but combination products face more complex labeling, abuse-control, and consumer-safety considerations. They also compete with established Zyrtec-D and store-brand equivalents.

How strong is the patent estate for DYE FREE WAL ZYR?

The patent estate is weak for the basic dye-free cetirizine tablet and potentially stronger for differentiated dosage forms.

Product concept	Patent strength	Main commercial barrier
Dye-free 10 mg tablet	Low	Cost, quality, retail access
Lactose-free tablet	Low to moderate	Formulation execution and branding
ODT cetirizine	Moderate	Taste masking, moisture protection, formulation claims
Chewable cetirizine	Moderate	Flavor and texture performance
Pediatric mini-tablets	Moderate	Dose flexibility and usability
Novel extended-release product	Moderate to high	Clinical, regulatory, and formulation requirements
Cetirizine combination product	Variable	Regulatory pathway and competitive pricing

A narrow patent on a particular excipient ratio may provide limited practical protection if competitors can design around it. Stronger protection usually requires a demonstrable technical result, such as rapid disintegration with acceptable taste, improved stability, or a controlled-release profile.

What commercial opportunities exist for DYE FREE WAL ZYR?

Private-label retailer expansion

Retailers can use dye-free cetirizine as a differentiated store-brand SKU without paying for a novel active ingredient. Opportunities include:

• 30-, 90-, and 365-count bottles
• Club-store multipacks
• Travel-size packages
• Seasonal allergy displays
• Retailer-exclusive packaging
• Subscription replenishment

The main value lies in procurement economics and customer retention. Exact Walgreens sales and margin data are not publicly disclosed at the individual SKU level.

Clean-label segmentation

The product can be extended into a broader "sensitive consumer" platform:

• Dye-free
• Lactose-free
• Gluten-free where supportable
• Sugar-free liquid
• Alcohol-free liquid
• Fragrance-free packaging
• Minimal-excipient tablet

Each claim requires substantiation and careful wording. "Dye-free" is commercially clearer and easier to validate than broad "clean-label" claims.

Pediatric formats

Pediatric allergy products offer a higher-value formulation opportunity than a standard adult tablet. Potential products include:

• 2.5 mg and 5 mg mini-tablets
• Dye-free chewables
• Fast-dissolving tablets
• Sugar-free oral solution
• Unit-dose liquid sachets

Palatability and dosing accuracy are the key development variables. A successful pediatric format can support premium pricing and reduce direct comparability with commodity 10 mg tablets.

E-commerce and adherence packaging

Online channels support larger counts, recurring orders, and targeted consumer search terms such as "dye-free allergy medicine" and "cetirizine without artificial colors." Unit-dose blister packs and calendar packaging can improve portability and adherence, although they increase packaging cost.

Contract manufacturing and licensing

The most practical licensing targets are:

• Dye-free film-coating systems
• Taste-masking technologies
• Moisture-resistant ODT platforms
• Pediatric mini-tablet manufacturing
• Low-cost high-speed compression processes
• Sustainable blister or bottle packaging

A conventional dye-free tablet is more likely to be sourced through a contract manufacturing agreement than protected through an exclusive technology license. Exclusive licensing becomes more defensible when the formulation includes a validated performance advantage.

What generic launch risks exist?

Generic and private-label launch risk is low at the active-ingredient level but remains meaningful operationally.

Risk	Impact
API supply interruption	Stockouts during peak allergy season
Blend uniformity failure	Batch rejection or recall
Dissolution variability	Regulatory and quality risk
Coating inconsistency	Appearance complaints and rework
Packaging defects	Moisture ingress or child-safety issues
Labeling error	FDA compliance and retailer recall exposure
Seasonal demand forecasting error	Excess inventory or missed sales
Retailer price competition	Margin compression
Consumer confusion with Zyrtec	Trademark and advertising scrutiny

The largest commercial risk is not patent litigation. It is failure to maintain supply during seasonal demand spikes while meeting retailer cost targets.

How does DYE FREE WAL ZYR compare with Zyrtec and other antihistamines?

Product	Active ingredient	Main differentiation	Exclusivity position
DYE FREE WAL ZYR	Cetirizine HCl	Retailer brand, dye-free positioning	No meaningful active-ingredient exclusivity
Zyrtec	Cetirizine HCl	Branded recognition	Mature, post-exclusivity product
Claritin	Loratadine	Often positioned as less sedating	Mature generic market
Allegra	Fexofenadine HCl	Low-sedation positioning	Mature generic market
Benadryl	Diphenhydramine HCl	Older antihistamine, broad recognition	Mature generic market

Cetirizine can cause drowsiness in some users, which limits differentiation based solely on safety or daytime use. A dye-free claim provides a narrower but credible positioning strategy. A superior commercial product would combine dye-free status with a meaningful usability benefit, such as better taste, faster disintegration, easier pediatric dosing, or more convenient packaging.

Key Takeaways

• DYE FREE WAL ZYR is a mature OTC cetirizine product differentiated mainly by private-label branding and dye-free positioning.
• The basic cetirizine tablet has weak patent protection and no meaningful current exclusivity barrier.
• Orange Book and Paragraph IV analysis are generally secondary for a conventional OTC monograph product.
• Excipient selection should prioritize content uniformity, rapid dissolution, manufacturability, stability, and acceptable labeling.
• The strongest formulation opportunities are pediatric mini-tablets, orally disintegrating tablets, chewables, liquids, and taste-masked products.
• Commercial upside is concentrated in retailer exclusivity, clean-label segmentation, large-count e-commerce packages, and seasonal supply execution.
• A novel excipient combination has limited value unless it produces a measurable technical benefit that supports enforceable claims.
• The principal launch risks are supply reliability, seasonal forecasting, quality failures, packaging compliance, and retail margin pressure.

FAQs

Is DYE FREE WAL ZYR the same as Zyrtec?

It is generally a private-label cetirizine product containing the same active ingredient, cetirizine hydrochloride. Inactive ingredients, tablet appearance, manufacturer, packaging, and quality specifications may differ.

Does dye-free cetirizine contain lactose?

Some cetirizine tablet formulations contain lactose, while others use different diluents. The inactive-ingredient statement for the specific NDC controls the answer.

Can a competitor patent a dye-free cetirizine tablet?

A broad patent on the concept alone would likely be difficult to sustain. A narrower patent could be possible if the formulation has a novel composition and a demonstrated technical advantage.

Is there biosimilar risk for cetirizine?

No. Cetirizine is a small-molecule drug, not a biologic. Competition comes from generic, OTC monograph, private-label, and branded products rather than biosimilars.

What is the best premium extension of DYE FREE WAL ZYR?

A pediatric or orally disintegrating formulation with validated taste masking and convenient dosing offers a stronger premium opportunity than another conventional 10 mg tablet.

References

1. U.S. Food and Drug Administration. (2024). Over-the-counter monograph M012: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products. FDA.

2. U.S. Food and Drug Administration. (2007). FDA approves over-the-counter Zyrtec for treatment of allergies. FDA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

4. U.S. Food and Drug Administration. (2024). Inactive Ingredient Database. FDA.

5. DailyMed. (2024). Cetirizine hydrochloride tablet labeling. U.S. National Library of Medicine.